Nautilus Biotechnology (NAUT) Operating Expenses (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Operating Expenses of $15.9 million for Q2 2026, down 1.15% sequentially from $16.1 million in Q1 2026, and down 6.78% YoY from $17.1 million in Q2 2025.
Nautilus Biotechnology (NAUT) Operating Expenses (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Operating Expenses for 7 years, with the latest figure at $15.9 million in Q2 2026.
- Quarterly Operating Expenses fell 6.78% year-over-year to $15.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $63.0 million (down 16.08% YoY) and the FY2025 annual result came in at $66.8 million, down 17.97% from the prior year.
- Operating Expenses eased to $15.9 million in Q2 2026 per NAUT's latest filing, from $16.1 million in the prior quarter.
- Over five years, Operating Expenses peaked at $21.6 million in Q1 2024 and troughed at $15.4 million in Q4 2025.
- A 5-year average of $17.8 million and a median of $17.6 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses jumped 90.35% in 2022, then dropped 22.8% in 2025.
- Over 5 years, Operating Expenses stood at $16.3 million in 2022, then rose by 22.68% to $20.0 million in 2023, then dropped by 0.1% to $20.0 million in 2024, then decreased by 22.8% to $15.4 million in 2025, then grew by 3.33% to $15.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $15.9 million, $16.1 million, and $15.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | 15.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.94 Mn |
| Mar 31, 2026 | 16.12 Mn |
| Dec 31, 2025 | 15.42 Mn |
| Sep 30, 2025 | 15.47 Mn |
| Jun 30, 2025 | 17.10 Mn |
| Mar 31, 2025 | 18.84 Mn |
| Dec 31, 2024 | 19.98 Mn |
| Sep 30, 2024 | 19.10 Mn |
| Jun 30, 2024 | 20.79 Mn |
| Mar 31, 2024 | 21.61 Mn |
| Dec 31, 2023 | 20.00 Mn |
| Sep 30, 2023 | 19.08 Mn |
| Jun 30, 2023 | 19.02 Mn |
| Mar 31, 2023 | 18.06 Mn |
| Dec 31, 2022 | 16.30 Mn |
| Sep 30, 2022 | 15.82 Mn |
| Jun 30, 2022 | 15.47 Mn |
| Mar 31, 2022 | 16.02 Mn |
| Dec 31, 2021 | 16.82 Mn |
| Sep 30, 2021 | 14.57 Mn |